MedPath

Evaluation of the Effects of an Exogenous Phytase on Iron Absorption From LNS Added to Complementary Foods

Not Applicable
Completed
Conditions
Iron Deficiency
Interventions
Dietary Supplement: Iron sulphate
Dietary Supplement: Iron pyrophosphate (FePP)
Dietary Supplement: micronutrient powder
Dietary Supplement: micronutrient powder (containing FeSO4), phytase
Registration Number
NCT01991626
Lead Sponsor
Swiss Federal Institute of Technology
Brief Summary

Previous studies on iron absorption have focused on the effects on the addition of iron absorption enhancers like ascorbic acid and EDTA to a meal and more recently the enzymatic phytic acid removal through phytase. The investigators want here to investigate the effects of fat on iron absorption with and without the addition of exogenous phytase as a potential iron absorption enhancer in lipid nutrient supplements (LNS) products compared to micronutrient powder(MNP) products.

Furthermore the investigators will evaluate the effects of Lipids- on iron absorption to induce the ileal brake by ingestion of a fat emulsion prior to a meal. Increasing the caloric density of a meal by increasing its fat content might enhance iron absorption by delaying gastric emptying, gastric acid secretion and increasing Fe stomach residence time.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
47
Inclusion Criteria

Reproductive age females 18-45 years

  • Normal body mass index (17.5-25 kg/m2)
  • No intake of mineral/vitamin supplements 2 weeks before and during the study
  • No metabolic or gastrointestinal disorders
  • No food allergies or other chronic disorders or eating disorders assessed by self-report
  • Having received full oral and written information about the aims and procedures of the study
  • Willing to comply with the study procedure
  • Having provided oral and written informed consent
Exclusion Criteria
  • Regular intake of medication (except oral contraceptives)
  • Blood donation or significant blood loss (accident, surgery) over the past 4 months
  • Currently participating in another clinical trial or having participated in another clinical trial during the last 30 days prior to the beginning of this study
  • Former participation in a study involving administration of iron stable isotopes
  • Subject who cannot be expected to comply with study protocol
  • Pregnancy or lactation

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
FeSO4- Emulsion beforeIron sulphateFat emulsion taken before a maize meal containing FeSO4
FePP-Emulsion mixedIron pyrophosphate (FePP)Fat emulsion mixed to the meal containing FePP
MNP-controlmicronutrient powdermaize meal containing micronutrient powder (MNP)
FeSO4 controlIron sulphateMaize meal containing FeSO4
FePP controlIron pyrophosphate (FePP)Maize meal containing FePP
FeSO4-MixedIron sulphatemeals containing FeSO4 mixed with a fat emulsion
LNS-Phytasemicronutrient powder (containing FeSO4), phytaseMaize meal mixed with LNS containing micronutrient powder and phytase
LNSmicronutrient powderMaize meal mixed with Lipid Nutrient Supplement (LNS) containing micronutrient powder
phytasemicronutrient powder (containing FeSO4), phytaseMaize meal containing micronutrient powder and phytase
FePP-Emulsion beforeIron pyrophosphate (FePP)Fat emulsion taken before a meal containing FePP
Primary Outcome Measures
NameTimeMethod
Iron bio-availability from Oral Iron Supplements14 days

Iron bioavailability will be assessed with stable isotopic labels. The shift in the isotopic ratio in human whole blood 14 days after administration will be measured with mass spectrometry.

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath